Eli Lilly (LLY) was down roughly 3% in Monday trading (May 4, 2026), pressured by a renewed bout of caution around its GLP-1 franchise after regulators asked the company to provide additional safety data for its newly approved oral obesity pill, Foundayo (orforglipron). The request reignited concerns that extra post-approval requirements—even if routine—can damp early adoption by physicians and slow payer decision-making, weighing on sentiment in a stock priced for continued GLP-1 upside. (zacks.com)

The pullback comes just days after Lilly surged on a blockbuster Q1 report and higher full-year outlook, which boosted expectations for 2026 profit growth and extended a strong run in the shares. With the stock coming off a rapid post-earnings move, any incremental uncertainty around the next leg of GLP-1 expansion can trigger profit-taking and multiple compression, especially with valuation-sensitive investors focused on execution risk. (marketbeat.com)

Key near-term swing factors include: (1) any clarity on the scope and timeline of the additional safety-data submission for Foundayo; (2) early signals from prescribers and payers on whether the request changes utilization; and (3) additional updates tied to federal access/coverage pathways for GLP-1s that may influence demand and net pricing. Investors will also watch whether the stock stabilizes after the post-earnings reset or continues to drift as the market re-prices regulatory and commercialization risk. (zacks.com)